

Resource Summary Report

Generated by [dkNET](#) on Sep 11, 2026

CD279

RRID:AB_2033988

Type: Antibody

Proper Citation

BD Biosciences Cat# 560838, RRID:AB_2033988

Antibody Information

URL: http://antibodyregistry.org/AB_2033988

Proper Citation: BD Biosciences Cat# 560838, RRID:AB_2033988

Target Antigen: CD279

Host Organism: mouse

Clonality: monoclonal

Comments: Flow cytometry

Antibody Name: CD279

Description: This monoclonal targets CD279

Target Organism: human

Antibody ID: AB_2033988

Vendor: BD Biosciences

Catalog Number: 560838

Record Creation Time: 20231110T072123+0000

Record Last Update: 20260901T033137+0000

Ratings and Alerts

No rating or validation information has been found for CD279.

No alerts have been found for CD279.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 5 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Zhou J, et al. (2026) Gut microbiota-derived indole-3-lactic acid suppresses anti-PD-1 efficacy in esophageal squamous cell carcinoma. *Cell host & microbe*, 34(4), 639.

Van Laethem JL, et al. (2025) CD40 agonist mitazalimab with mFOLFIRINOX in untreated metastatic pancreatic cancer: Biomarkers associated with outcomes from OPTIMIZE-1. *Cell reports. Medicine*, 6(10), 102407.

Pandit M, et al. (2023) Methionine consumption by cancer cells drives a progressive upregulation of PD-1 expression in CD4 T cells. *Nature communications*, 14(1), 2593.

Law H, et al. (2022) Early expansion of CD38+ICOS+ GC Tfh in draining lymph nodes during influenza vaccination immune response. *iScience*, 25(1), 103656.

Perrot I, et al. (2019) Blocking Antibodies Targeting the CD39/CD73 Immunosuppressive Pathway Unleash Immune Responses in Combination Cancer Therapies. *Cell reports*, 27(8), 2411.